clinical cases DDIs

Date of report 06 May 2019

Reported case interaction between **Dolutegravir** and **Oxcarbazepine**

Drugs suspected to be involved in the DDI

Victim
Dolutegravir

Daily Dose
50 (mg)

Dose adjustment performed
No

Administration Route
Oral

Start date
May 8, 2018

End date
Ongoing

Perpetrator
Oxcarbazepine

Daily Dose
600 (mg)

Dose adjustment performed
No

Administration Route
Oral

Start date
Jan. 1, 2017

End date
Ongoing

Complete list of drugs taken by the patient

Antiretroviral treatment

Dolutegravir/Abacavir/Lamivudine

Complete list of all comedications taken by the patient, included that involved in the DDI

Quetiapine, Risperidone, Olanzapine, Mirtazapine

Clinical case description

Gender

Male

Age

41

eGFR (mL/min)

>60

Liver function impairment

No

Description

HIV-infected patint diagnosed with depressive psychosis. On stable cARt with DTG/ABC/3TC since May 2018. Since 2017 on psychiatric treatment including oxcarbazepine 600 mg qd. Desptite the possibility of decreased dolutegravir exposure due to induction of UGT1A1 and CYP3A by oxcarbazepine HIV viral load in plasma persistently undetectable (<40 copies/mL). No blips.

Clinical Outcome

No unwanted outcome

Editorial Comment

Coadministration has not been studied but is expected to decreased dolutegravir exposure due to induction of UGT1A1 and CYP3A by oxcarbazepine. The US Prescribing Information advises to avoid coadministration due to insufficient data to make dosing recommendations. However, the European SPC suggests that dolutegravir be dosed at 50 mg twice daily, but recommends that alternative combinations should be used where possible in INSTI-resistant patients.

University of Liverpool Recommendation

■ Potential interaction - may require close monitoring, alteration of drug dosage or timing of administration

For more information click here